GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of
TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -- Announced new data showing GLIX1 achieved potent antitumor activity in
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in
Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies,
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and
Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses testedResults highlight GLIX1's potential to address
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData from the Phase 1 part of the
GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments
